UK markets open in 5 hours 13 minutes
  • NIKKEI 225

    28,980.85
    +472.30 (+1.66%)
     
  • HANG SENG

    28,812.61
    +190.69 (+0.67%)
     
  • CRUDE OIL

    61.11
    -0.24 (-0.39%)
     
  • GOLD FUTURES

    1,796.20
    +3.10 (+0.17%)
     
  • DOW

    34,137.31
    +316.01 (+0.93%)
     
  • BTC-GBP

    39,016.98
    -1,533.70 (-3.78%)
     
  • CMC Crypto 200

    1,258.57
    -4.39 (-0.35%)
     
  • ^IXIC

    13,950.22
    +163.95 (+1.19%)
     
  • ^FTAS

    3,935.64
    +15.59 (+0.40%)
     

U.S. FDA authorizes J&J’s COVID-19 vaccine

U.S. regulators authorized Johnson & Johnson’s COVID-19 vaccine for emergency use Saturday – one day after a panel of outside experts backed the one-shot immunization.

Now that it has the blessing of the Food and Drug Administration, J&J plans to ship three to four million doses next week.

On Thursday, President Joe Biden, pledged to quickly distribute J&J’s vaccine pending its approval.

"We have a plan to roll it out as quickly as Johnson & Johnson can make it.”

More than 50 million vaccine shots have been administered nationwide – a point Biden highlighted as the halfway point of his goal of vaccinating 100 million people in the first 100 days after taking office.

Distribution of J&J’s vaccine is a lot easier than those already available in the U.S. made by Pfizer/BioNTech and Moderna.

Its vaccine can be stored in normal refrigerator temperatures instead of ultra-cold storage. And it’s the only one that requires just a single shot.

A trial found that J&J’s vaccine was 66% effective at preventing moderate-to-severe cases of COVID-19. And it was 100% effective at preventing hospitalizations 28 days after vaccination.

The company is developing a second-generation vaccine that would target the more transmissible South African variant. It plans to start Phase 1 trials by this summer.